🟢 Recursion Pharmaceuticals is trading 4% up today after Tempus committed $42 million in payments

Recursion Pharmaceuticals is trading at $3.98 (+4.05%) on September 21, 2026, after expanding its Tempus AI partnership and licensing its TxFM RNA sequencing model.

• Tempus extended the data agreement through November 2029 and committed $42 million in payments.
• Broader risk-on sentiment supports the move, with the Nasdaq up 2.21% and AI-linked stocks leading gains.
• The partnership is the clearest company-specific catalyst.